MICHAEL ROBERTSON to Ipilimumab
This is a "connection" page, showing publications MICHAEL ROBERTSON has written about Ipilimumab.
Connection Strength
0.396
-
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026 Apr 30; 147(18):2041-2052.
Score: 0.237
-
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep; 7(9):e660-e670.
Score: 0.160